Lipidem (Omega-3-Acid Triglycerides, Soya-Bean Oil Refined, Triglycerides, Medium Chain)

The omega‑3‑acid triglycerides in Lipidem are hydrolyzed after infusion to release free fatty acids that become incorporated into phospholipid membranes, providing structural components and serving as an energy substrate. They also deliver essential polyunsaturated fatty acids that cannot be synthesized by the body, supporting inflammatory modulation and cellular processes.

The dosage of Lipidem is individualized by the prescribing clinician based on the patient’s caloric needs, weight, and clinical condition. The healthcare professional determines the volume and infusion rate to achieve the required percentage of total energy intake, typically expressed as grams of lipid per kilogram per day.

Safety data for Lipidem in pregnancy and lactation are limited. Because it is administered intravenously and provides essential fatty acids, it may be used when the benefits outweigh potential risks, but the decision should be made by the treating physician in consultation with obstetric specialists.

To place an order, submit an enquiry on the Lipidem product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Compared with traditional soybean‑oil based emulsions, Lipidem’s omega‑3‑acid triglyceride composition offers a higher proportion of polyunsaturated fatty acids, which may favorably influence inflammatory pathways and lipid profiles. However, clinical choice depends on patient‑specific factors, institutional protocols, and cost considerations.

Lipidem should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the container in its original packaging until use, and discard any product that appears discolored, separated, or has leaked.

Lipidem is given intravenously as a sterile lipid emulsion, typically infused through a dedicated line or Y‑site using an infusion pump. The rate is calculated by the clinician to meet the patient’s prescribed caloric and fatty acid goals, and the infusion set should be compatible with lipid solutions.

The most serious adverse events include anaphylactic reactions, severe hypertriglyceridemia that can precipitate pancreatitis, and fat overload syndrome, which may cause hepatic dysfunction, respiratory compromise, or coagulation abnormalities. Prompt recognition and discontinuation are essential if these events occur.

Lipidem is contraindicated in patients with known hypersensitivity to soy, egg phospholipids, or any component of the emulsion, as well as in individuals with severe hypertriglyceridemia, active pancreatitis, or uncontrolled sepsis. Use should be avoided in those with documented fat metabolism disorders unless closely monitored.